Merck to acquire EyeBio for an upfront $1.3bn
May 31, 2024Business Services EyeBio, Merck, Opthalmology, acquisition, ophthalmology
Merck, known as MSD outside of the US and Canada, and EyeBiotech Limited, have announced that the two companies have …
Eli Lilly and UNICEF expand support for young people at risk of noncommunicable diseases
May 30, 2024Medical Communications Eli Lilly, Pharmacy, Unicef, investment, noncommunicable diseases
Eli Lilly has announced that it will donate $6.5m to the United States Fund for UNICEF in order to expand …
Full-Life Technologies’ IND application for prostate cancer cleared by FDA
May 30, 2024Medical Communications Full-Life Technologies, IND, Oncology, prostate cancer
Full-Life Technologies has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application …
Sanofi’s Sarclisa accepted for FDA priority review
May 29, 2024Medical Communications FDA, Oncology, Sanofim, Sarclisa, multiple myeloma, priority review
Sanofi has announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for …
Merck shares data from phase 3 trial of Keytruda for TNBC treatment
May 29, 2024Medical Communications Merck, Oncology, breast cancer, clinical trial, keytruda
Merck, known as MSD outside of the US and Canada, has announced results from the phase 3 KEYNOTE-522 trial, which …
AstraZeneca shares results from phase 3 TROPION-Lung01 trial
May 28, 2024Medical Communications AstraZeneca, Daiichi Sankyo, NSCLC, Oncology, clinical trial, datopotamab deruxtecan
AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd). The survival …
Eli Lilly increases manufacturing investment to $9bn at new Indiana site
May 28, 2024Manufacturing and Production Diabetes, Eli Lilly, Indiana, investment, manufacturing
Eli Lilly has announced that it has more than doubled its investment at its Lebanon, Indiana, US manufacturing site with …
OSE Immunotherapeutics and Boehringer Ingelheim collaborate on cancer and cardio-renal-metabolic disease treatments
May 24, 2024Research and Development Boehringer Ingelheim, Cancer, Cardiology, OSE Immunotherapeutics, cardio-renal-metabolic diseases
OSE Immunotherapeutics and Boehringer Ingelheim have announced a major expansion of their existing partnership. The expansion includes two new projects …
Nona Biosciences announced agreement with AstraZeneca for tumour targeted therapies
May 24, 2024Research and Development AstraZeneca, Cancer, Oncology, nona biosciences, targeted therapies
Nona Biosciences and AstraZeneca have announced that the two companies have entered into a license agreement for preclinical monoclonal antibodies, …
BioGen to acquire Human Immunology Biosciences for $1.15bn
May 23, 2024Business Services Biogen, HI-Bio, Immunology, acquisition, immunology
BioGen and Human Immunology Biosciences (HI-Bio) have announced that they have entered into a definitive agreement for Biogen to acquire …
Merck to acquire Mirus Bio for $600m
May 23, 2024Business Services Merck, Pharmacy, acquisition, gene therapies
Merck has announced that it has signed a definitive agreement to acquire Mirus Bio for $600m.
Rare disease clinical trials: the urgent need for patients to be heard
May 22, 2024Alexion, Pharmafocus, Rare Diseases, clinical trials, feature
Ahead of Clinical Trials Day, Soraya Bekkali, from Alexion, AstraZeneca Rare Disease, highlights the urgent need to elevate patients’ voices …
Sustainability in pharma
May 22, 2024Pharmacy, Pharmafocus, feature, sustainability
Betsy Goodfellow from Pharmafocus considers the need for sustainable practices in the pharma industry and assesses various sustainable advances that have already …
Sanofi, Formation Bio and OpenAI enter AI collaboration
May 22, 2024Research and Development Formation Bio, OpenAI, Pharmacy, Sanofi, collaboration
Sanofi, Formation Bio and OpenAI have announced that they have entered into a collaboration with the aim of building AI-powered …
Eli Lilly shares positive results from phase 3 VIVID-1 trial of Crohn’s disease treatment
May 22, 2024Medical Communications Crohn’s disease, Eli Lilly, Endocrinology, clinical trial, mirikizumab
Eli Lilly has announced results from its pivotal phase 3 VIVID-1 study, which assessed patients with moderately to severely active …
GSK shares positive results from phase 3 asthma trials
May 21, 2024Research and Development Asthma & COPD, GSK, asthma, clinical trial
GSK has announced positive headline results from its phase 3 SWIFT-1 and SWIFT-2 trials, which evaluated the safety and efficacy …
J&J’s Tremfya meets primary and secondary endpoints in UC maintenance study
May 21, 2024Medical Communications Gastrointestinal tract, J&J, Johnson & Johnson, clinical trial, ulcerative colitis
Johnson & Johnson (J&J) has announced the first data from its phase 3 QUASAR maintenance study which assessed Tremfya (guselkumab) …
AstraZeneca to build $1.5bn ADC facility in Singapore
May 20, 2024Manufacturing and Production ADCs, AstraZeneca, Oncology, antibody drug conjugate, manufacturing
AstraZeneca has announced that it intends to build a $1.5bn manufacturing facility in Singapore, Singapore, for antibody drug conjugates (ADCs), …
ERS Genomics and IRBM sign license agreement for CRISPR/Cas9
May 20, 2024Research and Development CRISPR/Cas9, ERS Genomics, IRBM, License Agreement, Pharmacy
ERS Genomics and IRBM have announced that they have entered into a non-exclusive CRISPR/Cas9 license agreement, granting IRBM access to …
FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer
May 17, 2024Medical Communications Amgen, FDA, Oncology, lung cancer
Amgen has announced that the US Food and Drug Administration (FDA) has approved Imdelltra (tarlatamab-dlle) for the treatment of adult …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
